JNCE Jounce Therapeutics Stock Forecast Period (n+30) 19 Feb 2021


Stock Forecast


As of Sat Feb 20 2021 00:00:03 GMT+0000 (Coordinated Universal Time) shares of JNCE Jounce Therapeutics 2.74 percentage change in price since the previous day's close. Around 156550 of 39851000 changed hand on the market. The Stock opened at 10.98 with high and low of 10.98 and 11.78 respectively. The price/earnings ratio is: - and earning per share is -3.01. The stock quoted a 52 week high and low of 2.85 and 14.08 respectively.

BOSTON (AI Forecast Terminal) Fri, Feb 19, '21 AI Forecast today took the forecast actions: In the context of stock price realization of JNCE Jounce Therapeutics is a decision making process between multiple investors each of which controls a subset of design variables and seeks to minimize its cost function subject to future forecast constraints. That is, investors act like players in a game; they cooperate to achieve a set of overall goals.Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines. Machine Learning based technical analysis (n+30) for JNCE Jounce Therapeutics as below:
Using machine learning modified The random walk index model RWI equivalent to a model of stock market dynamics with price expectations, we analyze the reaction of investors to speculations. Analyzing those data we were able to establish the amount by which each stock felt the speculative attacks, a dampening factor which expresses the capacity of a market of absorving a shock, and also a frequency related with volatility after the speculation. Using the correlation matrices, the speculative buffer for the shares of JNCE Jounce Therapeutics as below:

JNCE Jounce Therapeutics Credit Rating Overview


We rerate JNCE Jounce Therapeutics because of a weaker market position, higher risk, or more confidence-sensitive mix of business is only partially offset by any strengths, and this leads us to expect weaker revenue stability relative to peers, thus demonstrating modest incremental risk above what is captured in the anchor. We use econometric methods for period (n+30) simulate with Envelope (ENV) Independent T-Test. Reference code is: 4819. Beta DRL value REG 12 Rational Demand Factor LD 6177.3516. If a company has a credit put that causes debt acceleration or collateral posting due to a downgrade of three notches or less, we would include these requirements under uses of liquidity, per paragraph 30 of the liquidity criteria. For example, if a 'BBB' rated company had a credit put that was triggered with a downgrade to speculative grade, we would include the corresponding cash requirement under uses of liquidity. This is because the criteria evaluate a company's liquidity position during times of stress, when potential downgrades are more likely. Credit Rating AI Process rely on primary sources of information: Sec Filings, Financial Statements, Credit Ratings, Semantic Signals. Take a look at Machine Learning section for Financial Deep Reinforcement Learning.

Oscillators are used for generating credit risk signals by using the semantic and financial signals. The value of the oscillators indicate the strength of trend. Using the correlation matrices, the risk map for JNCE Jounce Therapeutics as below:
Frequently Asked QuestionsQ: What is JNCE Jounce Therapeutics stock symbol?
A: JNCE Jounce Therapeutics stock referred as NASDAQ:JNCE
Q: What is JNCE Jounce Therapeutics stock price?
A: On share of JNCE Jounce Therapeutics stock can currently be purchased for approximately 11.23
Q: Do analysts recommend investors buy shares of JNCE Jounce Therapeutics ?
A: Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines. View Machine Learning based technical analysis for JNCE Jounce Therapeutics at daily forecast section
Q: What is the earning per share of JNCE Jounce Therapeutics ?
A: The earning per share of JNCE Jounce Therapeutics is -3.01
Q: What is the market capitalization of JNCE Jounce Therapeutics ?
A: The market capitalization of JNCE Jounce Therapeutics is 447526711
We work across the world

From London to San Francisco, to our home base in (Saint Helier) Jersey, we’re looking for extraordinary and creative scientists to help us drive the field forward.

Disclaimers: AC Investment Inc. currently does not act as an equities executing broker, credit rating agency or route orders containing equities securities. In our Machine Learning experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.The rating information provided is for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage as a credit rating or as a benchmark is not permitted.

77 Massachusetts Avenue Cambridge, MA 02139 617-253-1000 pr@ademcetinkaya.com